New PMCPA guidance on Package Deals

The PMCPA has published new guidance on package deals covering classification, governance, written agreements, communication and disclosure of transfers of value.

The PMCPA is aware from a current state analysis conducted in 2025, with input from stakeholders across pharmaceutical companies, service providers and healthcare organisations, that there are varying longstanding practices in relation to package deals among companies, particularly in relation to disclosure of transfers of value.

The PMCPA suggests that companies review all their ongoing package deals against this guidance as soon as possible.

Given the PMCPA is already aware of the varying practices related to disclosure of transfers of value for package deals, and given disclosure of transfers of value is a Code and not a legal requirement in the UK, the PMCPA has decided not to adjudicate on complaints related to disclosure of package deals transfers of value made between now and the end of June 2027. We hope that companies will make full use of this amnesty period to review their disclosure of transfers of value practices against this guidance and take appropriate action to update the information on Disclosure UK that is still in the public domain.

If companies have questions on the guidance, please email info@pmcpa.org.uk. The PMCPA plan to publish an ‘on demand’ training webinar in February and will try to address all questions received by the end of January within this webinar. 

We would like to thank the ABPI and all individuals and organisations that were involved in the development of this guidance.